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Mutations in the filamin C gene (FLNC) cause a myofibrillar myopathy (MFM), morphologically characterized
by focalmyofibrillar destruction and abnormal accumulation of several proteinswithin skeletalmuscle fibres.We
studied 31 patients from four German families to evaluate the phenotype of filaminopathy. All patients har-
boured the same p.W2710X mutation in FLNC. Haplotype analysis suggested a founder mutation in these
German filaminopathy families.The mean age at onset of clinical symptoms was 44 +/2 6 years (range, 24^57
years). Slowly progressive muscle weakness was mostly pronounced proximally, initially affecting the lower
extremities and involving the upper extremities in the course of disease progression, similar to the distribution
of weakness seen in limb-girdlemuscular dystrophies (LGMD). Patients frequently developed respiratorymuscle
weakness. About one-third of the patients showed cardiac abnormalities comprising conduction blocks, tachy-
cardia, diastolic dysfunction and left ventricular hypertrophy indicating a cardiac involvement in filaminopathy.
Serum creatine kinase levels varied from normal up to 10 -fold of the upper limit. Magnetic resonance imaging
studies showed a rather homogenous pattern ofmuscle involvement in the lower extremities differing from that
in other types of MFM.Myopathological features included perturbation of myofibrillar alignment, accumulation
of granulofilamentous material similar to that seen in primary desminopathies and abnormal intracellular pro-
tein deposits typical of MFM.Decreased activities of oxidative enzymes and fibre hypertrophy seem to be early
features, whereas dystrophic changes were present in advanced stages of filaminopathy. Rimmed vacuoles were
detected in only a few cases.The intracellular aggregates were composed of a variety of proteins including fila-
min C, desmin, myotilin, Xin, dystrophin and sarcoglycans.Therapy is so far limited to symptomatic treatment.
The German filaminopathy cohort, the largest group of patients studied so far, shares phenotypic features with
LGMD and presents with characteristic histopathological findings of MFM.
Keywords: filamin C; FLNC mutation; phenotype; myofibrillar myopathy; muscular dystrophy
Abbreviations: FSHD= facioscapulohumeral muscular dystrophy; LGMD=limb-girdle muscular dystrophies;
MFM=myofibrillar myopathy.
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Introduction
Myofibrillar myopathies (MFM) are a genetically hetero-
geneous group of chronic neuromuscular disorders mor-
phologically characterized by focal disintegration of
myofibrils and abnormal accumulation of several proteins
within skeletal muscle fibres. Clinical phenotype and age of
onset vary. In most patients, progressive muscle weakness
affecting proximal as well as distal muscles begins in
adulthood. Life expectancy may be shortened by associated
cardiomyopathy or due to involvement of respiratory
muscles. Cataract and peripheral neuropathy occur in a
subset of patients indicating a multi-system involvement
(Selcen et al., 2004). In a minority of cases, mutations in
desmin (DES, OMIM 125660) (Goldfarb et al., 1998),
myotilin (TTID, OMIM 604103) (Selcen and Engel, 2004),
ZASP (LDB3, OMIM 605906) (Selcen and Engel, 2005) and
aB-crystallin (CRYAB, OMIM 123590) (Vicart et al., 1998)
are associated with MFM. In 2005, we identified the first
pathological mutation in the filamin C gene (FLNC, OMIM
102565) in members of an extended family of German
origin with progressive muscle weakness and morphologic
features of MFM (Vorgerd et al., 2005).
Filamins are a family of large cytoskeletal proteins that
crosslink F-actin filaments into either parallel bundles or
dynamic three-dimensional meshwork. Moreover, they
interact directly with a plethora of cellular proteins of
great functional diversity, indicating that they are multi-
functional signalling adapter proteins (Stossel et al., 2001;
van der Flier et al., 2002 Feng and Walsh, 2004; Popowicz
et al., 2006;). The human filamin family consists of three
isoforms, filamins A, B and C. Mutations in filamin A and
B have been reported to cause a broad range of congenital
malformations, affecting brain, bone and other organs
(Robertson et al., 2003; Bicknell et al., 2007). Filamin C
(formerly also called filamin 2, g-filamin or ABP-L) is the
muscle-specific filamin isoform. Its upregulation during the
initial stages of myocyte differentiation, its localization
predominantly at the periphery of Z-disks and its direct
interaction with myotilin (van der Ven et al., 2000b) and
FATZ/calsarcin/myozenin (Faulkner et al., 2000;Takada
et al., 2001) imply an important role of filamin C during
myofibrillogenesis (Chiang et al., 2000;van der Ven et al.,
2000a;van der Ven et al., 2000b). At the sarcolemma,
filamin C interacts with g- and d-sarcoglycan in costameres
(Thompson et al., 2000) and with Xin in myotendinous
junctions (van der Ven et al., 2006). The p.W2710X
mutation in FLNC identified in our large German family
results in the inability of the mutant protein to dimerize
and in the development of large filamin C-containing
aggregates within the skeletal muscle fibres (Vorgerd et al.,
2005).
Here we report on the clinical, genetic, radiological and
myopathological features in 31 patients from four German
families with MFM associated with the p.W2710X mutation
in FLNC.
Patients and methods
Patients
Data of a total of 31 patients from four German families were
evaluated (Fig. 1, Table 1). 23 individuals (family 1: 11 patients,
family 2: six patients, family 3: two patients, family 4: four
patients) with the p.W2710X mutation in FLNC were examined
clinically. Clinical data of eight deceased patients from families
1 (Table 1, ID 1–6), 3 (ID 24) and 4 (ID 27) were obtained from
attending physicians and relatives. Genetic and preliminary clinical
data of family 1 have recently been reported (Vorgerd et al., 2005).
Fig. 1 Pedigrees of four German families with MFM associated with p.W2710X mutation in FLNC. Individuals with proven mutation and
deceased family members who had suffered from muscle weakness are represented by filled symbols.
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Table 1 Clinical data of 31 patients harbouring the p.W2710X mutation in FLNC
ID; sex; age at
onset/examination/death
Initial symptoms/distribution
of muscle weakness and muscle
atrophy
CK increase Cardiac findings Respiratory
insufficiency
EMG/NCS
Family 1
1; w; 40/?/61 Waddling gait/P4D, LL4UL n.k. n.k. Yes n.k.
2; w; 52/?/73 Unsteady gait/P4D, LL4UL n.k. n.k. Yes n.k.
3; w; ?/?/69 Waddling gait/P4D, LL4UL, para-
spinal muscles
No Cardiomyopathy (n.s.) Yes n.k.
4; w; 42/?/64 Unsteady gait/P4D, LL4UL 52-fold n.k. Yes n.k.
5; m; 43/?/68 Weakness when climbing stairs, lower
back pain/P4D, LL4UL, paraspinal
muscles
6-fold n.k. Yes n.k.
6; w; 45/49/64 Weakness when climbing stairs, leg
pain/P4D, LL4UL
3-fold Cardiomyopathy (n.s.) Yes n.k.
7; w; 37/64/alive Weakness when climing stairs, back
pain/P4D, LL4UL, winged scapula
2-fold Normal Yes n.d./n.d.
8; m; 45/62/alive Weakness when climbing stairs, lower
back pain/P4D, LL4UL, winged
scapula, mild ptosis
6-fold Normal Yes sA/normal
9; m; 45/58/alive Waddling gait, lower back pain/P4D,
LL4UL,winged scapula
8-fold Normal No mP/normal
10; w; 49/54/alive Waddling gait, lower back pain/PLL,
mild ptosis
3-fold Normal No mP/normal
11; w; 44/48/alive Weakness in legs, lower back pain/
PLL4DLL, PUL
2-fold Normal No mP/normal
12; m; 57/60/alive Weakness when climbing stairs or
walking uphill/P4D, LL4UL,
abdominal and paraspinal muscles,
winged scapula
2-fold RBBB, decreased EF No mP/normal
13; w; 43/50/alive Weakness when climbing stairs and
walking uphill/foot extensor
muscles4gluteal muscles & dorsal
thigh
4-fold Normal No n.d./n.d.
14; w; 46/48/alive Waddling gain, weakness when climb-
ing stairs, lower back pain/proximal-
dorsal and distal-anterior lower
extremities
2-fold Normal No n.d./n.d.
15; w; 50/52/alive Weakness when climbing stairs/P4D,
LL4UL, abdominal and paraspinal
muscles
3-fold Normal No n.d./n.d.
16; w; 49/54/alive Weakness when climbing stairs/P4D,
LL4UL
5-fold Atrial flutter, TA Yes n.d./n.d.
17; m; -/28/alive Asymptomatic 52-fold Normal No n.d./n.d.
Family 2
18; m; 45/49/alive /P4D, LL4UL, wheelchair-bound 3-fold Normal No sA/normal
19; w; 42/45/alive /P4D, LL4UL 2-fold Normal No sA/n.d.
20; w; 44/54/54 Weakness when climbing stairs or
walking uphill/P4D, LL4UL,
abdominal and paraspinal muscles,
winged scapula, facial muscles
(slight), wheelchair-bound at the age
of 52
3-fold Normal Yes sA/normal
21; w; 44/52/alive Back pain/P4D, LL=UL, neck muscles 2-fold RBBB, DD, grade II MG No sA/normal
22; w; 42/49/alive Weakness when climbing stairs or
walking uphill/P4D, LL=UL,
abdominal and paraspinal muscles,
winged scapula, facial muscles
(slight)
2-fold LVH, DD, grade I AG No sA/normal
23; m; 39/45/alive Weakness when climbing stairs/P4D,
LL4UL, paraspinal muscles
10-fold LVH No sA/normal
Family 3
24; w; 47/-/70 Waddling gait/P4D, LL4UL, wheel-
chair-bound at the age of 52
n.k. n.k. Yes n.d.
25; m; 48/55/alive Waddling gait/PLL n.k. n.k. No n.d.
(continued)
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Patients underwent echo- and electrocardiographic evaluations
following standard protocols. Examinations obtained left ventricular
dimensions, volumes and analysis of systolic, diastolic and valvular
function. Neurophysiological studies included routine electromyo-
graphic measurements and standard nerve conduction studies. In 10
patients (family 1: seven patients, family 2: two patients, family 4:
one patient), a skeletal muscle biopsy was performed. One patient
(ID 9) was biopsied twice at the age of 52 and 62 years.
Genetic analysis
Blood samples from all family members were obtained after written
informed consent. Genomic DNA was purified from peripheral
blood following standard methods using the QIAamp DNAMini Kit
(QIAGENGmbH, Hilden, Germany). The presence of the p.W2710X
mutation was analysed in all family members using the Big Dye
Terminator v 1.1 Cycle Sequencing Kit on an ABI 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Haplotype studies were performed on eight DNA samples of
affected members from the four apparently unrelated German
families. Six polymorphic microsatellite markers on chromosome
7q32.1 flanking the FLNC gene and the c.8130G4A FLNC
mutation were used for haplotyping: D7S635, D7S504, D7S1875,
D7S530, D7S2544 and D7S2519. Genomic locations are from the
UCSC reference database via http://www.genome.ucsc.edu/.
Haplotype analysis was performed as described previously
(von der Hagen et al., 2006).
Histochemical and immunofluorescence analysis
For conventional histochemical studies, 6 mm thick frozen sections
of unfixed skeletal muscle were processed for haematoxylin-eosin
(H&E), Gomori trichrome, acid phosphatase, periodic acid-Schiff
(PAS), NADH dehydrogenase, succinate dehydrogenase (SDH),
cytochrome c oxidase (COX), Congo red, adenosine triphos-
phatase (ATPase) at pH 4.3, 4.6, 9.4 and oil red O-staining using
standard procedures. The ATPase 9.4 staining was used for the
quantification of fibre types.
Immunofluorescence studies were performed on 4 mm thick
frozen serial sections. Primary antibodies used in this study are
listed in Table 2. Isotype-specific secondary antibodies conjugated
with fluorescein isothiocyanate or biotinylated sheep anti-mouse IgG
followed by Cy2-labelled streptavidin (Amersham Biosciences) were
applied according to the recommendations of the manufacturer.
Adjacent sections in the series were stained with Gomori trichrome.
Electron microscopy
Electron microscopy was performed on the second muscle
specimen of Patient 9. The specimen was fixed in 2.5%
glutaraldehyde and processed for electron microscopy by standard
methods. Ultrathin skeletal muscle sections were analysed using a
Zeiss 900 electron microscope at an accelerating voltage of 80 kV.
Desmin immunogold staining was performed as described
previously (Schro¨der et al., 2002).
MRI of skeletal muscle
Seven patients from families 1 and 3 (ID 9–12, 21–23) underwent
MRI of the lower extremities with a 1.5 Tesla MR unit
(MAGNETOM Symphony QUANTUM, Siemens, Erlangen,
Germany; maximum gradient 30mT/m, slew rate 125 T/m/s).
A four-channel phased array body coil was used. After acquiring
T1-weighted localizers of the lower extremities, axial T2-weighted
Turbo Inversion Recovery Magnitude (TIRM) images (TR 4020/
3040ms, TE 68/27ms, TI 150ms, slice thickness 10mm) and T1-
weighted non-fat-saturated Spin Echo images (TR 500ms, TE
20ms, slice thickness 10mm) were obtained.
Results
p.W2710X mutation in filamin C: a founder
mutation in the German filamin myopathy
population
Sequencing the FLNC gene identified a recently reported
p.W2710X mutation (Vorgerd et al., 2005) in all clinically
Table 1 Continued
ID; sex; age at
onset/examination/death
Initial symptoms/distribution
of muscle weakness and muscle
atrophy
CK increase Cardiac findings Respiratory
insufficiency
EMG/NCS
26; w; 43/50/alive Waddling gait, myalgia PLL/PLL4PUL n.k. Normal Yes sA/normal
Family 4
27; w; 48/?/75 ?/?, at the age of 65 respirator
dependent
No RBBB Yes sA/normal
28; w; 45/56/alive Back pain, weakness when climbing
stairs/P4D, LL4UL, wheelchair-
bound, paraspinal muscles, neck
muscles, facial muscles (slight)
3-fold LVH Yes sA/normal
29; m; 38/48/alive Back and neck pain/PUL4PLL, neck
muscles
3-fold Normal No sA/normal
30; w; 24/24/alive Back and neck pain/head flexors No Normal No sA/n.d.
31; w; -/25/alive Asymptomatic No Normal No n.d./n.d.
ID=patient identification number; CK=creatine kinase; EMG=electromyography; NCS=nerve conduction studies; w=woman;
m=man; P=proximal; D=distal;UL=upper limbs; LL, lower limbs; PUL=proximal upper limbs; PLL=proximal lower limbs; DLL=distal
lower limbs; EF=ejection fraction; RBBB=right bundle branch block; DD=diastolic dysfunction; MG=mitral regurgitation; AG=aortic
regurgitation; LVH= left ventricular hypertrophy; sA=spontaneous activity; mP=myogenic potentials; n.s.=not specified; n.k.=not
known; n.d.=not done.
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affected patients in the four German families (Fig. 1,
Table 2) and in two asymptomatic individuals (ID 17, 31)
from families 1 and 4. Haplotype studies revealed that the
carriers of the p.W2710X mutation share a common
haplotype stretching from marker D7S635 to D7S2519
including the FLNC gene region. In one patient (ID 26), a
recombination event occurred between markers D7S1875
and D7S530 with the assumed breakpoint proximal to the
p.W2710X FLNC mutation (Table 3). These findings
indicate a founder FLNC mutation in the German
filaminopathy families.
Clinical spectrum of patients
The mean age of onset was 44 6 years (range 24 to 57 years,
Table 1). Nine affected persons (ID 1–6, 20, 24, 27) died at a
mean age of 66 years (range 54 to 75 years). The distribution
of muscle weakness was evaluated in 28 symptomatic patients
either by clinical examination or anamnestic data. One patient
had only weakness of the neck flexors (ID 30). The other 27
patients suffered from slowly progressive skeletal muscle
weakness initially affecting the lower extremities and mostly
involving the upper extremities in the course of disease
progression. In 25/28 symptomatic patients, the weakness was
more pronounced proximally than distally (Fig. 2). One
patient (ID 14) showed distal and proximal weakness of the
leg muscles, and in one patient (ID 13) the weakness was
clearly distal. A slight involvement of facial muscles was seen
in five patients (ID 8, 10, 20, 22, 28). It is noteworthy that
10/28 patients (ID 7–11, 14, 21, 28–30) reported on back pain
as an initial symptom. Serum creatine kinase levels varied
from normal values up to 10-fold of the upper normal limit.
Neurophysiological studies were performed in 16 patients
(Table 1). In 12 patients, EMG revealed spontaneous
activity like fibrillation potentials, positive sharp waves
and complex repetitive discharges. Myogenic low amplitude
and polyphasic potentials were detected in four patients
(ID 9–12). One patient (ID 21) reported on hypaesthesia in
distal lower extremities but neurographic measurements did
not indicate a peripheral neuropathy in any of the patients.
Fourteen out of 31 patients including 9/9 deceased patients
suffered from weakness of respiratory muscles at time of
examination or at the end of lifetime (Table 1). At least two
patients (ID 6, 20) died because of severe respiratory
complications. Two patients (ID 7, 8) with a disease duration
of more than 15 years required nocturnal ventilation.
Echocardiographic and electrocardiographic evaluation
showed abnormalities in 9/25 patients (Table 1). Findings
included right bundle branch block (3/25; ID 12, 21, 27),
atrial flutter (ID 16) and left ventricular hypertrophy (3/25;
ID 22, 23, 28). One patient (ID 12) presented with
decreased ejection fraction and two patients (ID 21, 22)
with diastolic dysfunction. Cardiomyopathy with left
ventricular dysfunction was observed in two patients
during follow-up (ID 3, 6). The majority of patients had
normal ventricular volumes, dimensions and ejection
fraction. Findings of minor regurgitations of aortic or
mitral valve were observed in 2/25 patients (ID 21, 22).
Haemodynamical relevant valve dysfunctions and pericar-
dial effusion were not present.
Histological features
The histological findings in eleven skeletal muscle biopsies
taken from 10 patients at different stages of the disease
Table 2 Primary antibodies used in immunofluorescence studies
Antigen Clone Source Company/reference Dilution
Filamin C RR90 mouse (mAb) van der Ven et al. (2000a) 1/20
Desmin D33 mouse (mAb) DAKO 1/500
Myotilin RS034 mouse (mAb) Novocastra 1/20
aB-crystallin G2JF rabbit (pAb) Novocastra 1/100
Xin XR1B mouse (mAb) van der Ven et al. (2006) 1/5
a-sarcoglycan Ad1/20A6 mouse (mAb) Novocastra 1/100
b-sarcoglycan bSarc/5B1 mouse (mAb) Novocastra 1/100
g-sarcoglycan 35DAG/21B5 mouse (mAb) Novocastra 1/100
d-sarcoglycan dSarc3/12C1 mouse (mAb) Novocastra 1/100
Dystrophin Dy8/6C5 mouse (mAb) Novocastra 1/20
Spectrin RBC2/3D5 mouse (mAb) Novocastra 1/70
Caveolin 3 26 mouse (mAb) Transduction 1/200
Merosin (80kd) 5H2 mouse (mAb) Chemicon 1/150
Merosin (300 kd) Mer3/22B2 mouse (mAb) Novocastra 1/100
CollagenVI 3C4 mouse (mAb) Chemicon 1/500
a-actinin RBC2/1B6 mouse (mAb) Novocastra 1/1000
Slow myosin WB-MHCs mouse (mAb) Novocastra 1/40
Fast myosin WB-MHCf mouse (mAb) Novocastra 1/20
Titin 9D10 mouse (mAb) Chemicon 1/50
Filamin A mAB1680 mouse (mAb) Chemicon 1/300
mAb=monoclonal antibodies; pAb=polyclonal antibodies.
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varied from slightly unspecific changes to distinct muscular
dystrophy-like features (Table 4, Fig. 3). In Patient 10, a
muscle biopsy taken 4 years after clinical manifestation only
showed a small increase of endomysial collagen, internal
nuclei in four percent of muscle fibres, a few COX-negative
fibres and slightly hypertrophic type 1 and type 2 muscle
fibres. Similar changes were present in the first biopsy of
Patient 9 taken 7 years after clinical onset. In addition,
a few muscle fibres with core-like features were detected
(similar to findings in patient 28 shown in Fig. 3F, I, L).
The second biopsy in this patient taken 10 years later
showed a drastic increase of myopathic changes comprising
pronounced fibre size variability, fibre splitting, muscle
fibre necrosis and regeneration (like in Fig. 3A–E), rimmed
and non-rimmed vacuoles (like in Fig. 3B–E), endomysial
fibrosis and fatty replacement. Many fibres harboured
multiple internal nuclei. Core-like features were found in
about 20% of muscle fibres, predominantly in those with
Fig. 2 Pictures of patient 9 (A,B) and patient 12 (C,D). Note the predominantly proximal atrophies. Both patients present with winged
scapula (B,C).
Table 3 Haplotype analysis of selected filaminopathy patients from four German families
Marker Type Location (bp) ID 11
(family 1)
ID 23
(family 2)
ID 26
(family 3)
ID 28
(family 4)
D7S635 MS 126 960 896 4 6 4 1 4 5 4 1
D7S504 MS 127 302 461 2 1 2 3 1 3 2 4
D7S1875 MS 127 437 907 4 3 4 1 3 1 4 1
FLNC c.8130G4A (p.W2710X) Mutation 128 257 719 A G A G A G A G
D7S530 MS 128 889 656 3 1 3 1 3 4 3 3
D7S2544 MS 129 595 304 2 1 2 3 2 2 2 2
D7S2519 MS 129 650 934 3 2 3 2 3 4 3 3
MS=microsatellite markers. Columns represent individual haplotypes of the analysed patients. Each row represents the genotypes of the
MS and the FLNC mutation. Markers are listed from centromeric to telomeric.The values in bold represent haplotype cosegregating with
the p.W2710X mutation (representing a putative founder haplotype).
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Table 4 Histological findings in ten filaminopathy patients
Family 1 2 4
Patient ID 6 9 9 (re-biopsy) 10 11 12 15 16 19 23 28
Age at biopsy (years) 54 52 62 53 48 61 52 50 46 42 46
Site of biopsy D VL GN VL VL GN GN VL VL VL BB
Morphological changes
Necrosis - - + - (+) + + + + + +
Fibre splitting - - + - - + ++ + - - (+)
Internal nuclei ++ (+) +++ + ++ +++ ++ + (+) - ++
Rimmed vacuoles - - + - (+) + - - - - +
Core-like features (+) (+) +++ - ++ +++ ++ ++ + ++ ++
COX-negative fibres (+) + + (+) (+) (+) - - - - (+)
Fibre regeneration (+) - + - (+) ++ - - - - +
Increase of endomysial collagen Moderate Mild Moderate Mild Moderate Severe Moderate Severe Mild Mild Moderate
Neurogenic changes No No Yes No No Yes Yes No No Yes Yes
Morphometrical studies
Type 1 [%]/Typ 2 [%] fibres 80/20 57/43 52/48 48/52 61/39 74/26 70/30 49/51 46/54 58/42 76/24
Typ 1 fibres
Mean diameter [mm] (range) 51 (20^120) 69 (41^102) 72 (21^144) 65 (51^85) 52 (16^92) 64 (11^160) 77 (28^132) 61 (33^108) 59 (28^116) 82 (30^126) 41 (6^117)
Hypotrophic fibres [%] 10 - 15 - 3 15 2 1 1 2 26
Hypertrophic fibres [%] 8 21 34 32 8 23 56 29 28 54 2
Typ 2 fibres
Mean diameter [mm] (range) 53 (28^110) 80 (47^108) 44 (7^180) 64 (40^80) 66 (17^89) 59 (13^157) 79 (25^140) 69 (30^105) 45 (26^93) 61 (33^113) 46 (10^90)
Hypotrophic fibres [%] 5 - 66 - 3 24 2 2 3 3 14
Hypertrophic fibres [%] 15 49 24 23 42 20 54 48 2 6 2
D=deltoideus muscle; VL=vastus lateralis muscle; GN=gastrocnemius muscle; BB=biceps brachii muscle; (+)/+/++/+++, existent in51/1up to 5/6 up to 20/more than 20% of muscle
fibres.
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abnormal areas in trichrome staining as described below.
Dystrophic changes were even more pronounced in Patient
12 (Fig. 3A). A predominance of type 1 fibres was detected
in most biopsies (Table 4, Fig. 3J). Possible neurogenic
changes such as denervation atrophy (Fig. 3J) were
present in 5/11 biopsies (ID 12, 15, 23, 28, second biopsy
of ID 9, Table 4).
In all muscle specimens except the one from Patient 10,
muscle fibres with light microscopic features of abnormal
protein aggregation were observed at different degrees.
Fig. 3 Histochemical findings in muscle specimen of patient12 (A) and patient 28 (B^L). (A) Dystrophic pattern with pronounced fibre size
variability, internal nuclei, fibre splitting, muscle fibre necrosis and regeneration, endomysial fibrosis and fatty replacement. (B), (E), (H),
(K) Serial consecutive sections with MFM-typical histological findings, congophilic deposits and PAS-positive vacuols. (C), (F), (I), (L) Serial
sections show sharply circumscribed decreases of oxidative enzyme activity. (D) Unequal distribution of abnormal fibres across the fasci-
cles. (G) Increased acid phosphatase activity in abnormal fibres. (J) Predominance of type I fibres. Insert: cluster of atrophic fibres of both
fibre types. (A,B): HE (C^E): Gomori trichrome; (F): COX; (G): acid phosphatase; (H): Congo red; (I): NADH dehydrogenase; (J): ATPase
9.4; (K): PAS; (L): SDH. Bar in (J) (also applies to A, D)=100mm, bar in (L) (also applies to B,C, E^I, K)=50mm.
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These fibres typically appeared in uneven distribution across
the fascicles (Fig. 3D). In trichrome-stained sections,
abnormal fibres harboured a variety of pleomorphic hyaline,
granular and amorphous deposits ranging from red-blue to
dark-blue in colour. These inclusions varied in size, quantity
and localization within the affected fibres (Figs 3C–E and 4).
Some fibres harboured vacuoles in variable size and location
partly rimmed or filled with basophilic membranous material
(Fig. 3B–E). Non-rimmed vacuoles frequently showed strong
PAS-positivity (Fig. 3K). Most inclusions in abnormal fibres
were congophilic (Fig. 3H). Activities of oxidative enzymes
and ATPase were decreased or lacking in abnormal fibre
regions (Fig. 3F, I, L). Core-like features were detected in
fibres of 10/11 biopsies (Table 4). Those fibres were often
inconspicuous in trichrome-stained sections. Many abnormal
fibres showed increased acid phosphatase levels (Fig. 3G).
Immunofluorescence studies
Immunofluorescence analysis indicated strong immunore-
activities for filamin C, desmin, aB-crystallin and Xin in
areas appearing abnormal in trichrome-stained sections
(Fig. 4). Ectopic cytoplasmic expression of g-sarcoglycan,
dystrophin (Fig. 4), caveolin-3, a-, b-, d-sarcoglycan,
merosin (80 and 300 kDa), spectrin and collagen VI were
present in many abnormal fibres. Abnormal areas showed
no immunoreactivity for a-actinin, myosin, titin or filamin
A. Small intracellular protein accumulations were detected
sporadically in the first biopsy of Patient 9 but were more
prominent and very abundant in the second one taken 10
years later. Remarkably, the biopsy of Patient 10 did not
show any pathological protein aggregates (Fig. 4).
Ultrastructural features
Ultrastructural analysis of the second skeletal muscle biopsy
of Patient 9 showed widespread myofibrillar pathology
comprising rod formation (also visible in trichrome-stained
sections), Z-disc remnants, Z-disc streaming and myofi-
brillar lysis. Multiple muscle fibres displayed subsarcolem-
mal and intermyofibrillar pathological protein aggregates
consisting of filamentous or desmin-positive granulo-
filamentous material. In this context, it is noteworthy that
the granulofilamentous material observed in filaminopathies
is morphologically indistinguishable from the one seen in
primary desminopathies and aB-crystallinopathies. In
addition, single fibres contained sarcoplasmic paired helical
filaments (Fig. 5).
MRI findings
MRI showed progressive lipomatous changes of the lower
limb muscles in all seven patients with high signal intensities
of the affected muscles on non-fat-saturated T1-weighted
images. The lipomatous alterations exhibited an almost
identical, symmetrical involvement of muscle groups in the
lower limbs in comparison of the patients (Fig. 6).
Predominantly, the following muscles were affected: gluteal
muscles, semimembranosus, adductor magnus and longus,
biceps femoris, vastus intermedius and medialis, soleus,
medial head of gastrocnemius, tibialis anterior, extensor
hallucis longus and extensor digitorum longus. The abnormal
findings included reticular patterns of hyperintensity on
T1-weighted images in less affected patients (ID 10), whereas
homogeneous areas of T1w hyperintensity were visible in
individuals with progressive disease (Fig. 6). Typically, the
sartorius and gracilis, the superficial parts of the quadriceps
femoris and the lateral head of the gastrocnemius appeared
almost normal (arrowheads in Fig. 6) even in patients with
more advanced clinical course. Muscular signal intensities on
T2-weighted TIRM images were only mildly elevated in the
examined patient group primarily affecting the muscles
mentioned above, indicating absence of distinct intramus-
cular oedema (Fig. 6).
Discussion
In the present study, we report a large series of patients
with genetically proven filamin C mutation. Filaminopathy
in these patients is characterized by an onset of symptoms
at a mean age of 44 years, a prominent proximal weakness
more in lower than upper extremities, resembling the
typical phenotype of limb-girdle-muscular dystrophy, with
involvement of respiratory muscles in the disease course
and hints suggesting cardiac involvement in a subset of
patients. In all the patients, we found the same p.W2710X
mutation in the FLNC gene described before in an extended
German family (Vorgerd et al., 2005), which is transmitted
in an autosomal dominant manner. Even though a
relationship between the families was not apparent or
known to the families, haplotype analyses strongly indicate
a founder mutation.
Filaminopathy shows typical histopathological
findings of MFM and decreased activities
of oxidative enzymes indicate an early
mitochondrial dysfunction
Selcen et al. defined minimal criteria required for the
histopathological diagnosis of MFM: (i) pleomorphic
abnormal fibre regions in trichrome stained sections,
(ii) vacuolar changes in some fibres, (iii) immunolocaliza-
tion of multiple proteins in most pleomorphic fibre regions,
and (iv) congophilia of some hyaline deposits (Selcen,
2006). Nine out of ten filaminopathy patients biopsied
fulfilled these MFM criteria and showed a perturbation of
myofibrillar alignment including disintegration of Z-disks
at the ultrastructural level. Similar features have been
reported in desminopathy (Ba¨r et al., 2005; Goldfarb et al.,
2004), aB-crystallinopathy (Selcen and Engel, 2003),
myotilinopathy (Olive et al., 2005; Selcen and Engel,
2004), ZASPopathy (Selcen and Engel, 2005), and MFM
patients with unknown mutation (Selcen et al., 2004).
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Therefore a differentiation between subtypes of MFM on
the basis of histological findings alone is not possible and
needs molecular genetic studies.
Interestingly, COX-negative fibres and core-like lesions
without any typical MFM changes in trichrome staining or
immunofluorescence studies were early signs of filamino-
pathy. In analogy to a previously described case of primary
desminopathy (Schro¨der et al., 2003), these findings
indicate that mitochondrial changes may be an early
histological sign in MFM. In patients with muscle weakness
and focally decreased oxidative enzyme activities, beside a
primary mitochondriopathy MFM should also be consid-
ered even if typical histological MFM features are lacking.
Within the clinical diversity of MFM,
filaminopathy resembles a limb-girdle
muscular dystrophy phenotype
Clinical presentation of MFM has been very variable. Onset
may be in childhood or in the teens with sudden death
Fig. 4 Immunofluorescence findings in filaminopathy. Studies on muscle specimen of clinically affected patient 10 indicate neither
abnormal fibre regions in trichrome-stained section nor immunoreactivity for any protein tested. In patients 9 and 12, serial consecutive
sections are shown. Note accumulation of filamin C, desmin, aB-crystallin, myotilin and Xin (all three series) as well as ectopic expression
of g-sarcoglycan and dystrophin (patient 9 at age 62, patient 12) in fibres that appear abnormal in trichrome-stained sections.
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Fig. 6 Magnetic resonance imaging in four filaminopathy patients. The images show slices of the proximal and distal upper legs and of the
proximal lower legs. T1w signal hyperintensities denote lipomatous changes to complete fatty degeneration of affected muscles. TIRM
hyperintensities represent oedematous changes. Patient 9 shows symmetrical T1w hyperintense signal changes of the upper legs in the
extensor muscle groups, principally of the vastus medialis, proximal vastus intermedius and lateralis with less pronounced involvement of
the rectus femoris and distal vastus lateralis (arrowheads), and the complete adductor muscle groups; hamstring involvement is primarily
restricted to the biceps femoris with relative sparing of the semitendinosus and semimembranosus muscles. The gracilis and sartorius
muscles are basically spared (arrowheads) in all patients. Lower leg involvement is almost complete with sparing of the lateral heads of the
gastrocnemius muscles (arrowheads) and faint remaining signal in the peroneal groups and tibialis posterior muscles. Slight hyperintense
TIRM signal changes are seen in the vastus lateralis and gastrocnemius muscles. Patient 10 displays far less pronounced lipomatous changes.
Upper leg involvement comprised mainly of adductor and hamstring muscles. The lower legs also show relative sparing of the lateral gas-
trocnemius muscles (arrowheads) with reticular fatty changes of the medial gastrocnemius muscles, peroneal and anterior tibial groups and
complete fatty degeneration of the deep flexor and tibialis posterior groups. TIRM images indicate discrete signal changes in the medial
gastrocnemius heads. Patient 11 has pronounced lipomatous changes of the upper legs with complete involvement of the adductors and
hamstrings.The lower legs show a pattern similar to Patient 9. Epifascial TIRM hyperintensities of the tibialis anterior muscles (arrow) are
presumably secondary to exertion.The upper legs in patient12 showT1w hyperintensities in the adductor and hamstring groups, the latter
with semitendinosus sparing; the lower legs are similarly affected as in patient 10.
Fig. 5 Ultrastructural analysis of skeletal muscle from patient 12. (A) Note the presence of a myofibrillar Z-disc (arrow), Z-disc remnants
(arrowheads) and adjacent filamentous deposits (asterix) (Bar=0.6mm). (B) Illustration of myofibrillar rods (arrowhead) and paired helical
tubulofilamentous inclusions (Bar=0.6mm). (C) Immunogold electron microscopy using a monoclonal anti-desmin antibody (mAb, clone
D33) in conjunction with a secondary antibody coupled to 10nm gold particles revealed a dense labelling of intermyofibrillar granulofila-
mentous material (Bar=0.4mm).
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from cardiac complications as observed in desminopathy
with autosomal recessive inheritance (Goldfarb et al., 2004),
but most often the first clinical symptoms appear in
adulthood (Selcen et al., 2004). A predominant involvement
of distal muscles is seen in the majority of patients with
myotilinopathy (Olive et al., 2005; Selcen and Engel, 2004)
(Table 5). In ZASPopathy, patients with the p.A165V
or p.R268C mutations presented with distal myopathy,
whereas some patients with the p.A147T mutation showed
proximal or proximal and distal muscle weakness (Griggs
et al., 2007; Selcen and Engel, 2005) (Table 4). In
aB-crystallinopathy, patients harbouring the p.R120G mis-
sense mutation had proximal and distal weakness (Fardeau
et al., 1978; Fardeau et al., 2000) whereas two patients with
the 464delCT and p.Q151X mutation presented with
prominent distal weakness (Selcen and Engel, 2003).
Clinical features in desminopathy are very heterogeneous
(Goldfarb et al., 2004) and more than 30 different
mutations have been identified so far (Olive et al., 2007;
Walter et al., 2007). Members of a large Ashkenazi Jewish
family with p.L345P desmin mutation suffered from distal
weakness predominantly in the lower extremities (Horowitz
and Schmalbruch, 1994; Sjo¨berg et al., 1999). In a series of
12 patients with 7 different desmin mutations, 6 patients
had distal and 6 patients proximal as well as distal weakness
(Dalakas et al., 2000). In a recently reported series of 15
German patients with the p.R350P desmin mutation, a
limb-girdle phenotype was described in 10 of them, whereas
a scapuloperoneal phenotype and a distal myopathy was
seen in two patients each (Walter et al., 2007) (Table 5).
This indicates that the clinical phenotype in MFM not only
depends on the gene affected but also on the precise
mutation and additionally large interindividual variation
may occur in patients with identical mutations.
In this series of filaminopathy patients presented here,
proximal weakness was found in 25 out of 28 affected
individuals and a clearly distal myopathy was only seen in
one patient. Therefore, filaminopathy associated with
p.W2710X mostly leads to a limb-girdle muscular dystro-
phy (LGMD)-like phenotype and can not be distinguished
from a muscular dystrophy by clinical examination alone.
The presence of marked winged scapula (Fig. 2) can be
similar to that frequently seen in facioscapulohumeral
muscular dystrophy (FSHD) but facial involvement was
only present in a subset of filaminopathy patients and not
as pronounced as in typical FSHD.
As we only studied patients with the same p.W2710X
founder mutation the comparatively homogeneous clinical
phenotype of filaminopathy has to be proven in patients
with different FLNC mutations. So far, only two further
patients with filaminopathy have been identified in a cohort
of 70 MFM patients investigated at the Mayo Clinic (Selcen,
2006) and the mutation was identical to that in our patients
(Selcen, personal communication). It would be interesting
to investigate by haplotype analysis whether these two
patients share the German founder haplotype.
MRI findings are homogenous in
filaminopathy (p.W2710X) and differ
from other MFM subtypes
Muscle-imaging studies presented here show a rather
homogenous pattern of muscle involvement. When these
MRI data were compared with other types of MFM, the
alterations in proximal leg muscles were significantly more
pronounced in filaminopathy compared to myotilinopathy
and ZASPopathy (Fischer et al., submitted for publication).
In primary desminopathies, the sartorius, gracilis and
semitendinosus muscles are more affected than in filamino-
pathy whereas involvement of vastus intermedius and
medialis, adductor magnus, semimembranosus and biceps
femoris muscles was more pronounced in filaminopathy.
These findings indicate that muscle-imaging studies may be
helpful to distinguish between the different MFM subtypes.
Respiratory muscle weakness is a frequent
complication in filaminopathy
In our four filaminopathy families, all nine deceased patients
evaluated and five still living patients suffered from weakness
of respiratory muscles. Restrictive respiratory failure has also
been documented in aB-crystallinopathy (Fardeau et al.,
1978; Selcen and Engel, 2003), myotilinopathy (Olive et al.,
2005) and desminopathy (Goldfarb et al., 2004; Olive
et al., 2007; Walter et al., 2007), whereas in ZASPopathy res-
piratory muscle involvement has not been described so far
(Table 5). This indicates that respiratory insufficiency occurs
frequently in MFM including the filaminopathy and may
reduce life expectancy markedly. Therefore, a careful and
regular respiratory follow-up in the disease course is essential.
Is there evidence for a cardiac and
peripheral nerve involvement in
filaminopathy?
Cardiac involvement is a frequent complication in MFM
(Table 5). For example, patients with the p.R120G mutation
in the aB-crystallin gene typically present signs of
hypertrophic cardiomyopathy (Vicart et al., 1998). Five
out of 18 patients with myotilinopathy had cardiac findings
including left and right bundle branch block and congestive
heart failure leading to death in one patient (Selcen and
Engel, 2004; Olive et al., 2005). In ZASPopathy, cardiac
involvement in terms of conduction defects and arrhythmia
was reported in 3 out of 10 patients harbouring the
missense mutations p.A147T and p.A165V in ZASP exon
6 (Selcen and Engel, 2005) (Table 5). Exon 6 is expressed in
cardiac transcripts of ZASP and mutations in this exon have
previously shown to be associated with cardiomyopathy
(Vatta et al., 2003). Desminopathy has the highest
prevalence of cardiac involvement in all types of MFM
with known mutations described so far. About half of the
patients investigated in studies listed in Table 5 were
affected. In a more recent study, six out of seven patients
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Table 5 Phenotypic characteristics of patients with genetically proven myofibrillar myopathy
Study N Type of
inheritance
Mutation(s) Onset
age
Prominent muscle
weakness
Peripheral
neuropathy
Cardiac
involvement
Respiratory
insufficiency
CKactivity EMG findings
Myotilinopathy
Selcen et al.
(2004)
6 AD (1/6) p.S60C (3/6),
p.S60F (1/6),
p.S95I (1/6),
p.S55F (1/6)
50^77 2/5
3/5
Proximal LL
Distal LL
6/6 3/5 n.r. Normal^
2-fold
1/5
4/5
Myopathic
Myopathic-neurogenic
Olive et al.
(2005)
13 AD (5/13)
De novo
(7/13)
p.K36E (1/13),
p.S55F (6/13),
p.S60C (4/13),
p.S60F (1/13),
p.Q74K (1/13)
42^77 2/13
1/13
Proximal LL
Proximal-distal
1/13 2/13 3/13 Normal^
4-fold
10/11
1/11
Myopathic
Myopathic-neurogenic
ZASPopathy
Selcen et al.
(2005)
11 AD p.A147T (7/11),
p.A165V (3/11),
p.R268C (1/11)
44^73 2/11
3/11
6/11
Proximal
Proximal-distal
Distal (3/3 A165V)
5/11 3/11 0/11 Normal^
6-fold
8/11
2/11
Myopathic
Myopathic-neurogenic
Neurogenic
Griggs et al.
(2007)
10 AD p.A165V 44^49 6/6 Distal LL n.r. n.r. n.r. n.r. 1/11 n.r.
Desminopathy
Horowitz
et al. (1994)
Sjo« berg et al.
(1999)
12 AD p.L345P 24^46 10/10 Distal (7/10 LL4UL) 0/9 7/12 3/6 Normal^
4-fold
6/9 Myopathic
Dalakas et al.
(2000)
12 AD (7/12)
CH (3/12)
De novo
(2/12)
p.A337P (2/12),
p.I451M (3/12),
p.N342D (2/12),
p.R406W (1/12),
p.A360P/p.N393I (3/12)
20^43 6/12
6/12
Proximal-distal
Distal (5/6 LL)
n.r. 7/12 2/12 Normal^
4-fold
n.r.
Walter et al.
(2007)
15 AD p.R350P 30^50 6/15
2/15
5/15
2/15
Proximal (LL4UL)
Proximal-distal
(LL4UL)
Distal LL
Scapuloperoneal
4/8 7/15 7/15 Normal^
16-fold
9/15
3/15
Myopathic
Myopathic-neurogenic
Filaminopathy
Present study 31 AD p.W2710X 24^57 25/28
1/28
1/28
1/28
Proximal (19/21 LL4UL)
proximal-distal LL
distal LL
neck flexors
(5/28) 9/24 14/30 Normal^
10-fold
14/15 Myopathic
CK=creatine kinase; EMG=electromyography; AD=autosomal dominant; CH=compound heterozygote; LL, lower limbs; UL, upper limbs; increased; n.r.=not reported.
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with different mutations in desmin had cardiomyopathy
(Olive et al., 2007). Findings included cardiac arrhythmias
and conduction blocks up to complete AV block requiring
implantation of a permanent pacemaker, dilated cardio-
myopathy, left ventricle diastolic dysfunction, restrictive
cardiomyopathy and congestive heart failure. Some patients
died of cardiac complications before age 30 (Goldfarb et al.,
2004; Olive et al., 2007). In this series of filaminopathy
patients, about one-third showed cardiac abnormalities
comprising conduction blocks, tachycardia, diastolic dys-
function and left ventricular hypertrophy. Since filamin C is
expressed in striated muscles including cardiac muscle
(Maestrini et al., 1993), these findings indicate that
p.W2710X mutation may induce cardiac pathology.
However, this hypothesis has to be verified in heart
muscle specimens of filaminopathy patients or appropriate
filamin C mouse models.
Peripheral nerve involvement assessed by clinical, neuro-
physiological or histological criteria has been described in a
subset of MFM patients (Table 5) and postmortal studies in
one desminopathy patient detected axonal spheroidal
formations immunoreactive for neurofilaments in spinal
cord and spinal roots (Ariza et al., 1995). In our
filaminopathy cohort, muscle specimen of half of the
patients biopsied suggested neurogenic changes but nerve
conduction velocities were normal in all individuals
examined and only one person reported on distal
hypaesthesia. These findings are not sufficient to verify an
involvement of peripheral nervous system in filaminopathy
and have to be complemented by further studies such as
nerve biopsies.
Functional studies on the mutated filamin
C polypeptide provided insights into the
pathomechanisms of filaminopathy
The filamin molecule is composed of an amino-terminal
actin-binding domain followed by 24 immunoglobulin-like
modules. The most carboxy-terminally situated Ig-like
domain is required and sufficient for dimerisation
(Himmel et al., 2003), which enables the filamins to link
actin filaments into bundles or meshwork. The p.W2710X
mutation in FLNC causes a deletion of the carboxy-
terminal 16 amino acids. In vitro biochemical studies
revealed a less stable secondary structure of the Ig-like
domain 24 and a reduced structural stability of the mutant
protein (Vorgerd et al., 2005). As a consequence, the
mutant protein does not dimerize properly and has a strong
tendency for uncontrolled aggregation (Vorgerd et al., 2005;
Lo¨we et al., 2007). A variety of different proteins are
subsequently recruited into these aggregates, thereby
destabilizing tissue homoeostasis. Some of the proteins,
e.g. myotilin and Xin, detected by immunofluorescence in
aggregates or in ectopic distribution within muscle fibres of
patients are binding partners of filamin C (van der Ven
et al., 2000b; van der Ven et al., 2006). In adult skeletal
muscle the localization of Xin is normally restricted to the
myotendinous junction and there is evidence that Xin is
involved in developmental and adaptive remodelling of the
actin cytoskeleton in cross-striated muscle cells (van der
Ven et al., 2006). Filamin C also interacts with g- and
d-sarcoglycan, two members of the dystrophin-associated
glycoprotein complex which are deficient in LGMD 2C and
2F, respectively (Thompson et al., 2000). As a result of the
ectopic accumulation of g- and d-sarcoglycan, the connec-
tion of the myofibrillar cytoskleleton to the extracellular
matrix may be weakened and the dystrophin-associated
signalling affected (Lo¨we et al., 2007).
Symptomatic therapy is mandatory in
filaminopathy
To date, no specific therapy is available for filaminopathy
and the other subtypes of MFM. Symptomatic treatment
should consider respiratory and cardiac complications and
frequent respiratory and cardiological function tests are
necessary during the disease course. Since respiratory
insufficiency increases the risk of chest infections, patients
may require intermittent or continuous positive pressure
ventilation. Treatment of conduction blocks, arrhythmias
and cardiac hypertrophy must follow cardiological guide-
lines. Regular physical therapy may help to maintain muscle
strength but excessive training should be avoided because of
potential damage of myofibres (Goldfarb et al., 2004). The
efficacy of creatine treatment, which has been shown to
increase muscle strength in muscular dystrophies (Kley
et al., 2007), should be investigated by controlled trials.
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